Swiss Pediatric Inflammatory Bain Disease Cohort Study
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland opened for recruitment after that: Aarau, Basel, Bellinzona, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur and Zurich. The center in Fribourg is expected open for recruitment in 2025. The registry provides data for national and international monitoring and research. It supports research on inflammatory brain diseases in Switzerland and the exchange of knowledge between clinicians, researchers, and therapists. The registry aims to improve the treatment of children with inflammatory brain diseases and optimizing their health care and quality of life.
⁃ All patients living and/or treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18.
• Written informed consent by patients (and/or legal representative(s), if applicable)
• Optic Neuritis
• Transverse Myelitis
• Acute disseminated encephalomyelitis
• Multiple Sclerosis
• Neuromyelitis Optica Spectrum Disorders
• Myelin oligodendrocyte glycoprotein antibody-associated disease
• Anti-NMDA-R Encephalitis
• Anti-GAD65 Associated Autoimmune Encephalitis
• Anti-AMPAR-1/2 Associated Autoimmune Encephalitis
• Anti-Lgi-1 Associated Autoimmune Encephalitis
• Anti-CASPR-2 Associated Autoimmune Encephalitis
• Anti-GABAR-1/2 Associated Autoimmune Encephalitis
• Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis
• Hashimoto Encephalopathy
• CNS Vasculitis
• CNS Sarcoidosis
• CNS Lupus
• Rasmussen Encephalitis